


PHARMACEUTICAL 2022

ROYALTY PHARMA

## Royalty Pharma plc Rank 209 of 466







PHARMACEUTICAL 2022

Royalty Pharma plc Rank 209 of 466

The relative strengths and weaknesses of Royalty Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Royalty Pharma plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 221% points. The greatest weakness of Royalty Pharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 160% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 72% points above the market average of 78%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 2,878,211            |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 5,670                |
| Liabilities, Current                        | 171,250              |
| Liabilities, Non-Current                    | 7,096,070            |
| Other Assets                                | 14,631,984           |
| Other Compr. Net Income                     | -643,619             |
| Other Expenses                              | 475,838              |
| Other Liabilities                           | 0                    |
| Other Net Income                            | -189,514             |
| Other Revenues                              | 2,289,463            |
| Property and Equipment                      | 0                    |
| Research and Development                    | 200,084              |
| Selling, General and Administrative Expense | 182,826              |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 17,515,865           |
| Liabilities              | 7,267,320            |
| Expenses                 | 858,748              |
| Revenues                 | 2,289,463            |
| Stockholders Equity      | 10,248,545           |
| Net Income               | 1,241,201            |
| Comprehensive Net Income | 919,392              |
| Economic Capital Ratio   | 150%                 |

